Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology Patients
Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Massimiliano Berretta(University of Messina), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Celeste Fonderico(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfredo Mauriello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Stefano Oliva(Istituto Tumori Bari), Matteo Barbato(University of Milan), Anna Chiara Maratea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marino Scherillo, Maria Laura Canale(Ospedale Versilia), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Raffaele Arianna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Christian Cadeddu Dessalvi(University of Cagliari)
Cited by 4
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective
|Frontiers in Physiology|2018|154
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
|Antioxidants and Redox Signaling|2017|122
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116